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A5. SAFETY WITH REGARD TO THE ENDOMETRIUM IN THE ESPRIT
TRIAL
H.C. Kitchener. University of Manchester, Oxford Road, Manchester, M13 9PC,
UK
Estrogen in the Prevention of Reinfarction Trial (ESPRIT) was a placebo-
controlled randomised control trial (RCT) of 24 months oestradiol valerate (2
mg) to determine if it could prevent reinfarction or cardiac death in women who
had had a myocardial infarction. The trial did not show any beneﬁt from
oestradiol valerate, but oﬀered the opportunity to observe the eﬀects of
unopposed oestradiol on the endometrium.
Subjects had a median age of 62.5 years and had been, on average postmen-
opausal for 16 years. The hysterectomy rate was 24% and 11% had taken prior
hormone replacement therapy (HRT). The mean body mass index was 26 kg/m2.
Non-compliance with oestradiol rose from 29% at 3 months to 57% at 24
months, compared with 23% and 37%, respectively, for
placebo. Bleeding was the major reason for non-compliance, with
56% reporting bleeding in the oestradiol arm compared with only 7% for
placebo treated patients. Bleeding began within 6 months in 75% of the bleeders.
Of the 208 women who bled in the oestradiol group, 189 had an endometrial
biopsies with the following results; 112, no pathology; 57, simple hyperplasia; 12,
complex hyperplasia; 8, atypical hyperplasia; 0, endometrial carcinoma. All
complex and atypical hyperplasia were reversed with medroxyprogesterone
acetate, and cessation of oestradiol in the latter cases.
Comment: Oestradiol valerate commonly induced bleeding, but rarely produced
atypical hyperplasia. The reason for the occurrence of atypical hyperplasia in 4%
is not known.
doi:10.1016/j.ejcsup.2004.08.029
A6. FULVESTRANT (‘FASLODEX’) PREVENTS ENDOMETRIAL
GROWTH: A PHASE I TRIAL
Laight A. AstraZeneca Pharmaceuticals, Macclesﬁeld, Lancashire, UK
Tamoxifen has been the mainstay of breast cancer treatment for many years.
However, tamoxifen has partial oestrogen agonist activity that can increase
the risk of endometrial cancer with long-term exposure. Fulvestrant
(‘Faslodex’) is a new oestrogen receptor antagonist with no agonist eﬀects.
This double-blind, randomised trial evaluated the eﬀects of fulvestrant on the
endometrium of healthy post-menopausal volunteers, when given alone and in
combination with ethinyloestradiol (EE). Following a 14-day screening period
during which volunteers were assessed for a positive response to EE, 30
volunteers were randomised to receive fulvestrant 250, 125 mg or placebo as a
single intramuscular injection (providing pharmacokinetic exposure for at
least one month). Two weeks post-injection, volunteers received 2 weeks of
concurrent exposure to EE 20 lg /day. Endometrial thickness was measured
pre- and post-screening, pre-dose, and on days 14, 28, and 42 post-treatment.
Fulvestrant 250 mg signiﬁcantly inhibited EE-induced endometrial thickening
compared with placebo (P=0.0001). Neither fulvestrant 125 or 250 mg
demonstrated oestrogenic eﬀects on the endometrium during the 14-day
treatment period. Fulvestrant was well tolerated and reduced the incidence of
EE-related side-eﬀects. Fulvestrant 250 mg is an oestrogen receptor antagonist
with no evidence of agonist activity in the endometrium of healthy post-
menopausal women.
doi:10.1016/j.ejcsup.2004.08.031
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